General
Preferred name
DROPERIDOL
Synonyms
Dehydrobenzperidol ()
NSC 169874 ()
NSC 169874,Dehydrobenzperidol ()
NSC-169874 ()
Inapsine ()
Dridol ()
McN-JR-4749 ()
Droleptan ()
R-4749 ()
P&D ID
PD001512
CAS
548-73-2
Tags
natural product
drug
available
Approved by
FDA
First approval
1970
Drug Status
withdrawn
approved
vet_approved
Drug indication
Nausea
Antipsychotic
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Droperidol has sedative, tranquilising, and anti-nausea actions. (GtoPdb)
Cell lines
0
Organisms
1
Compound Sets
26
Axon Medchem Screening Library
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
DrugMatrix
Enamine BioReference Compounds
Guide to Pharmacology
Ki Database
LSP-MoA library (Laboratory of Systems Pharmacology)
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
NIH Clinical Collections (NCC)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
Withdrawn 2.0
External IDs
35
Properties
(calculated by RDKit )
Molecular Weight
379.17
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
1
Rotatable Bonds
6
Ring Count
4
Aromatic Ring Count
3
cLogP
3.68
TPSA
58.1
Fraction CSP3
0.27
Chiral centers
0.0
Largest ring
6.0
QED
0.66
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Pathway
GPCR/G protein
Neuroscience
Neuronal Signaling
Target
D2
ADRA1A, DRD2, DRD3, DRD4, HTR2A
D2/a1 antagonist
Dopamine Receptor
Indication
nausea, vomiting
MOA
Dopamine Receptor antagonist
ATC
N05AD08
Toxicity type
cardiovascular
Therapeutic Class
Antipsychotic Agents
Source data